摘要
目的:探讨曲美布汀联合多潘立酮治疗糖尿病胃轻瘫(diabetic gastroparesis,DGP)的临床疗效.方法:按照随机数字表法将武汉市普爱医院收治的86例DGP患者均分为实验组和对照组,实验组给予曲美布汀联合多潘立酮治疗,对照组仅给予多潘立酮治疗,比较两组患者疗程结束后临床疗效、治疗前后胃固体半排空时间(gastric solid half emptying time,GET1/2)、不良反应发生情况以及随访2 mo复发情况.结果:实验组患者治疗总有效率显著高于对照组(93.02%vs 74.42%),差异具有统计学意义(P<0.05);两组患者治疗后GET1/2均显著下降,与治疗前比较,(124.49 min±23.05min vs 225.62 min±21.88 min,199.46 min±23.49 min vs 222.62 min±19.08 min),差异具有统计学意义(P<0.05);实验组患者治疗后GET1/2显著低于对照组(124.49 min±23.05min vs 199.46 min±23.49 min),差异具有统计学意义(P<0.05);两组患者用药后不良反应发生率比较(0.00%vs 4.65%),差异无统计学意义(P>0.05);实验组患者随访2 mo复发率显著低于对照组(13.95%vs 51.16%),差异有统计学意义(P<0.05).结论:曲美布汀联合多潘立酮治疗可有效改善DGP患者临床症状及GET1/2,临床疗效显著,应用和推广价值较高.
AIM： To assess the clinical effects of trimebutine maleate combined with domperidone in the treatment of diabetic gastroparesis（DGP）.METHODS： Eighty-six patients with DGP were randomly divided into either an experiment group or a control group. The experiment group was treated with trimebutine maleate combined with domperidone, and the control group was treated with domperidone alone. The clinical effects, gastric emptying half-time（GET1/2）, adverse reactions, and relapse were compared for the two groups.RESULTS： The total effective rate for the experiment group was significantly higher than that for the control group（93.02% vs 74.42%, P〈0.05）. The GET1/2 post-treatment for the two groups was significantly lower than that priortreatment（124.49 min ± 23.05 min vs 225.62 min± 21.88 min, 199.46 min ± 23.49 min vs 222.62 min ± 19.08 min, P〈0.05）. There was no significant difference in the rate of adverse reactions for the two groups（0.00% vs 4.65%, P〉0.05）. The rate of relapse at 2 mo for the experiment group was lower than that for the control group（13.95% vs 51.16%, P〈0.05）.CONCLUSION： Trimebutine maleate combined with domperidone can improve clinical symptoms and GET1/2 in patients with DGP.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第29期4478-4481,共4页
World Chinese Journal of Digestology
